Literature DB >> 1376785

Regional hemodynamic effects and clearance of endothelin-1 in humans: renal and peripheral tissues may contribute to the overall disposal of the peptide.

S Gasic1, O F Wagner, H Vierhapper, P Nowotny, W Waldhäusl.   

Abstract

We investigated the regional balance of endothelin-1 across the renal and leg vascular bed as well as the hemodynamic effects of exogenously administered endothelin-1 in six healthy men. Net regional endothelin-1 balance was calculated from the respective arteriovenous differences in plasma concentrations and the corresponding plasma flow, the latter being determined by para-aminohippurate or indocyanine-green dye using appropriate catheter techniques. During constant intravenous (i.v.) infusion of endothelin-1 (0.4 pmol/kg/min), a slight increase in diastolic blood pressure (p less than 0.05) and a decrease in heart rate (p less than 0.01) were observed. In contrast, no significant changes in leg hemodynamics were noted. Renal plasma flow decreased by approximately 30%, and renal vascular resistance increased by 50% as compared with the control (placebo) period (p less than 0.01). Renin plasma concentrations did not change substantially during endothelin-1 infusion. During the control (placebo) period, arterial endothelin-1 plasma concentrations averaged 2.1 +/- 1.0 pM. An equilibrated peptide balance across the leg and a slight renal uptake of endothelin-1 was observed. After endothelin-1 infusion, arterial plasma concentrations of the peptide increased to 4.9 +/- 1.3 pM (p less than 0.01), and a net overall renal and limb uptake of endothelin-1 accounted for approximately 9 and 6% of the infused endothelin-1 amount, respectively. Results showed that at systemic endothelin-1 plasma concentrations, comparable to those which occur in a variety of pathologic conditions such as hypertension or cardiogenic shock, besides pulmonary clearance, renal and limb uptake of the peptide may also contribute to the short half-life (t1/2) of endothelin-1 in humans.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1376785     DOI: 10.1097/00005344-199202000-00004

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  12 in total

1.  The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044.

Authors:  C Plumpton; C J Ferro; W G Haynes; D J Webb; A P Davenport
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

2.  Differential distribution of endothelin peptides and receptors in human adrenal gland.

Authors:  A P Davenport; S L Hoskins; R E Kuc; C Plumpton
Journal:  Histochem J       Date:  1996-11

Review 3.  Air Pollution-Induced Vascular Dysfunction: Potential Role of Endothelin-1 (ET-1) System.

Authors:  Jordan Finch; Daniel J Conklin
Journal:  Cardiovasc Toxicol       Date:  2016-07       Impact factor: 3.231

Review 4.  Endothelin in congestive heart failure.

Authors:  M P Love; J J McMurray
Journal:  Basic Res Cardiol       Date:  1996       Impact factor: 17.165

Review 5.  O-GlcNAcylation: a novel pathway contributing to the effects of endothelin in the vasculature.

Authors:  Victor V Lima; Fernanda R Giachini; David M Hardy; R Clinton Webb; Rita C Tostes
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-11-10       Impact factor: 3.619

Review 6.  Endothelin-1 and the kidney--beyond BP.

Authors:  Neeraj Dhaun; David J Webb; David C Kluth
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

7.  Regional haemodynamic responses to intravenous and intraarterial endothelin-1 and big endothelin-1 in conscious rats.

Authors:  S M Gardiner; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

8.  Endothelin-1 in children with chronic renal failure.

Authors:  I Blazy; M Déchaux; M Charbit; D Brocart; J C Souberbielle; M F Gagnadoux; F Guillot; C Sachs
Journal:  Pediatr Nephrol       Date:  1994-02       Impact factor: 3.714

Review 9.  The heart as an extravascular target of endothelin-1 in particulate matter-induced cardiac dysfunction.

Authors:  Elizabeth A W Chan; Barbara Buckley; Aimen K Farraj; Leslie C Thompson
Journal:  Pharmacol Ther       Date:  2016-05-21       Impact factor: 12.310

Review 10.  Endothelin.

Authors:  Anthony P Davenport; Kelly A Hyndman; Neeraj Dhaun; Christopher Southan; Donald E Kohan; Jennifer S Pollock; David M Pollock; David J Webb; Janet J Maguire
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.